[
  {
    "ts": null,
    "headline": "Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025",
    "summary": "FOSTER CITY, Calif., October 09, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update.",
    "url": "https://finnhub.io/api/news?id=66f6f87065ce10c74e0c9807606ba15c67593153a8fc8ed38e12b1d2337107ed",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760040300,
      "headline": "Gilead Sciences to Release Third Quarter 2025 Financial Results on Thursday, October 30, 2025",
      "id": 137041817,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "FOSTER CITY, Calif., October 09, 2025--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its third quarter 2025 financial results and guidance will be released on Thursday, October 30, 2025 after the market closes. At 4:30 p.m. Eastern Time that day, Gilead’s management will host a webcast to discuss the company’s third quarter 2025 financial results and provide a business update.",
      "url": "https://finnhub.io/api/news?id=66f6f87065ce10c74e0c9807606ba15c67593153a8fc8ed38e12b1d2337107ed"
    }
  },
  {
    "ts": null,
    "headline": "Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update",
    "summary": "Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model Well capitalized with cash and marketable securities of $428.8 million SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage b",
    "url": "https://finnhub.io/api/news?id=863590cdc6af8f3b8b4bc69840160c6d927d67141f0b57a680c3183e8d8101a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760040060,
      "headline": "Nurix Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update",
      "id": 137041818,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "Announced clinical development plans for bexobrutideg, including the initiation of pivotal trials in relapsed/refractory CLL in H2 2025 Presented preclinical data at EADV 2025 for GS-6791 (NX-0479), a novel IRAK4 degrader in collaboration with Gilead, showing potent pathway inhibition and efficacy in a dermatitis model Well capitalized with cash and marketable securities of $428.8 million SAN FRANCISCO, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage b",
      "url": "https://finnhub.io/api/news?id=863590cdc6af8f3b8b4bc69840160c6d927d67141f0b57a680c3183e8d8101a4"
    }
  },
  {
    "ts": null,
    "headline": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
    "summary": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=daef52097fee83bf4e941c0a6519a9fee17c50f8f4f05db8b630f75159ea988f",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760027760,
      "headline": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
      "id": 137079498,
      "image": "",
      "related": "GILD",
      "source": "MarketWatch",
      "summary": "Gilead Sciences Inc. stock underperforms Thursday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=daef52097fee83bf4e941c0a6519a9fee17c50f8f4f05db8b630f75159ea988f"
    }
  },
  {
    "ts": null,
    "headline": "Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
    "summary": "SAN FRANCISCO, October 09, 2025--Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
    "url": "https://finnhub.io/api/news?id=9f8fb2a698cd96a2633be12fc5206adf31a371f2286841fddf29b2a4ea940be3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760011200,
      "headline": "Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
      "id": 137031300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "GILD",
      "source": "Yahoo",
      "summary": "SAN FRANCISCO, October 09, 2025--Expedition Therapeutics Raises $165 Million in Oversubscribed Series A Financing to Advance Next-Generation DPP1 inhibitor for COPD",
      "url": "https://finnhub.io/api/news?id=9f8fb2a698cd96a2633be12fc5206adf31a371f2286841fddf29b2a4ea940be3"
    }
  },
  {
    "ts": null,
    "headline": "My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys",
    "summary": "Discover September's top stock gains, AI-driven strategies, and high-yield BDC investments to boost passive income.",
    "url": "https://finnhub.io/api/news?id=8d23a2abebc98961046aa372ed04c412898c62c1483cedde798fbcf32b86519f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1760004000,
      "headline": "My Dividend Stock Portfolio: New September Dividend Record - 100 Holdings With 13 Buys",
      "id": 137032129,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1213764535/image_1213764535.jpg?io=getty-c-w1536",
      "related": "GILD",
      "source": "SeekingAlpha",
      "summary": "Discover September's top stock gains, AI-driven strategies, and high-yield BDC investments to boost passive income.",
      "url": "https://finnhub.io/api/news?id=8d23a2abebc98961046aa372ed04c412898c62c1483cedde798fbcf32b86519f"
    }
  }
]